




# BMJ Open Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences

Katherine Kenny ,<sup>1</sup> Leah Williams Veazey ,<sup>1</sup> Alex Broom,<sup>1</sup> Michelle Peterie,<sup>1</sup> Alexander Page,<sup>1</sup> Barbara Prainsack ,<sup>2</sup> Claire E. Wakefield,<sup>3,4</sup> Malinda Itchins,<sup>5,6</sup> Mustafa Khasraw,<sup>7</sup> Zarnie Lwin<sup>8,9</sup>

**To cite:** Kenny K, Williams Veazey L, Broom A, *et al.* Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences. *BMJ Open* 2023;**13**:e065753. doi:10.1136/bmjopen-2022-065753

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-065753>).

Received 15 June 2022  
Accepted 03 April 2023

## ABSTRACT

**Objectives** To explore informal caregivers' perspectives on precision medicine in cancer care.

**Design** Semi-structured interviews with the informal caregivers of people living with cancer and receiving targeted/immunotherapies. Interview transcripts were analysed thematically using a framework approach.

**Setting** Recruitment was facilitated by two hospitals and five Australian cancer community groups.

**Participants** Informal caregivers (n=28; 16 men, 12 women; aged 18–80) of people living with cancer and receiving targeted/immunotherapies.

**Results** Thematic analysis identified three findings, centred largely on the pervasive theme of hope in relation to precision therapies including: (1) precision as a key component of caregivers' hope; (2) hope as a collective practice between patients, caregivers, clinicians and others, which entailed work and obligation for caregivers; and (3) hope as linked to expectations of further scientific progress, even if there may be no personal, immediate benefit.

**Conclusions** Innovation and change in precision oncology are rapidly reconfiguring the parameters of hope for patients and caregivers, creating new and difficult relational moments and experiences in everyday life and in clinical encounters. In the context of a shifting therapeutic landscape, caregivers' experiences illustrate the need to understand hope as collectively produced, as emotional and moral labour, and as entangled in broader cultural expectations of medical advances. Such understandings may help clinicians as they guide patients and caregivers through the complexities of diagnosis, treatment, emerging evidence and possible futures in the precision era. Developing a better understanding of informal caregivers' experiences of caring for patients receiving precision therapies is important for improving support to patients and their caregivers.

## INTRODUCTION

The emergence of precision therapies over the past two decades has been accompanied by changed illness and survivorship experiences, most notably for patients, but also for informal caregivers (people who provide care that is unremunerated and within the context of an existing relationship, such as a family

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Our sample included participants involved in caring for people receiving targeted/immunotherapy for a wide range of cancer types.
- ⇒ Qualitative data are crucial to better understanding informal caregivers' experiences and to improving future services and supports.
- ⇒ Recruitment was undertaken nationally and interviews were conducted remotely, enabling participation across a range of settings.
- ⇒ The study design limits what can be claimed to prevail across time in changing oncology treatment contexts, although follow-up interviews with a subset of participants enabled some insights over time.
- ⇒ Recruitment for this study was limited to Australia; further investigations will be needed to explore similarities and differences across national contexts.

member or friend). In oncology, 'precision'—the molecular profiling of tumours in order to match them with particular treatments—has led to an increased focus on the identification of cancer biomarkers, and treatment with novel targeted or immune therapies. These precision therapies differ considerably from traditional standard of care treatments such as chemotherapy.<sup>1</sup> Although unequally available across contexts, new precision therapies have inspired renewed hope, catalysed escalating costs and produced new landscapes of side effects, patienthood and survivorship.<sup>2–6</sup>

While the impact of precision oncology on *disease* outcomes is relatively well documented,<sup>7</sup> its varied and evolving impacts on experiences of *survivorship* and *informal caring* have received limited emphasis.<sup>4</sup> This is despite the fact that targeted/immunotherapies, when viable and accessible, have radically transformed survivorship (eg, duration of treatment, types of side effects and symptoms)<sup>8</sup> and associated informal caring roles. While some attention has been paid



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

### Correspondence to

Dr Katherine Kenny;  
katherine.kenny@sydney.edu.au



to the emergence of ‘precision survivorship’ (surviving with/beyond targeted treatments/immunotherapy),<sup>8 9</sup> including initial studies of patient perspectives,<sup>5 10–12</sup> no research has foregrounded informal caregivers’ experiences and their interpretations of the precision turn in oncology. In this paper, we begin to fill this gap by delving into caregivers’ accounts of the *relational*, *affective* and *societal* dimensions of hope in the context of precision therapeutics.

## BACKGROUND

### Informal caregivers in cancer scholarship

The significance of informal caregivers, and the practical and emotional work they perform in supporting people living with cancer, has received increasing attention since the turn of the century.<sup>13 14</sup> Such research has shown the importance of understanding illness experiences and caregiving in relational terms.<sup>15–17</sup> The shift from an intimate partner or parent–child relationship, for example, to one of care-giver and care-recipient involves changes to roles and responsibilities, communication and decision-making dynamics, identities and emotions.<sup>14 17</sup> Moreover, coping with cancer diagnosis and treatment invariably happens within the context of myriad relationships.<sup>18</sup> Thinking about ‘dyadic coping’<sup>18</sup> and other forms of interdependence includes attending to the connectedness of caregiver experiences to the capacity of patients with cancer themselves to cope with intervention (precision or otherwise).<sup>19</sup>

Research conducted prior to the widespread availability of precision therapeutics emphasises that the type of care tasks performed, and the emotional impact on patients and caregivers, varies significantly across the cancer ‘journey’. During treatment aimed at recovery or disease control, patients and caregivers (particularly spousal carers) may construct a sense of cancer as a shared experience,<sup>18 20</sup> while a terminal diagnosis may fracture this sense of commonality as patient and caregiver diverge in their experiences of future time.<sup>21–24</sup> With therapeutic shifts and rapidly changing cancer trajectories, these relational dynamics and caregivers’ engagement require specific investigation.

### Precision medicine and survivorship

The advent of precision oncology has led to a paradigm shift in cancer research, trials and care.<sup>5 7</sup> For example, in advanced/metastatic non-small cell lung cancer (NSCLC), precision therapies have increased the median overall survival (OS) rate to 18–36 months (compared with 8–17 months with chemotherapy),<sup>25</sup> and for ALK-positive NSCLC the median OS has reached 6–8 years.<sup>26 27</sup> Similarly in metastatic breast cancer the introduction of trastuzumab in 2000 improved 5-year survival rates for HER2 positive patients from 2% to 31%.<sup>28</sup> New treatments continue to improve survival<sup>29</sup> and precision oncology is now associated with long-term remissions in a substantial proportion of HER2 positive patients.<sup>30</sup> Researchers

are hopeful that future innovative trials with molecularly matched tailored therapies will improve survival even further.<sup>31</sup> However, for those *currently* providing or receiving cancer care, these new therapeutic options can complicate decision-making about treatment pathways due to the constant emergence of new data.<sup>4</sup>

Beyond considerations of improved survival, patients’ experiences of precision cancer treatment may diverge dramatically from the well-trodden paths of surgery, chemotherapy and radiotherapy. Symptoms, side effects, costs, logistics and implications for everyday life may be very different. For example, patients may need to travel long(er) distances for trials or subspecialist care (especially patients in rural or remote areas), self-fund molecular testing or expensive drugs and manage family and community expectations about what living with cancer entails. This all has ramifications (financial, logistical, emotional) for families, partners and other supporters. The increasing entanglement of research and care<sup>4</sup> means it is vital to draw attention to the largely unrecognised embodied and emotional work by patients *and* caregivers that underpins cancer innovation.<sup>12 32</sup> In this changing landscape, patients and caregivers may need to adjust their understanding of success beyond binaries of cure or death. For precision oncology patients, ‘success’ may involve lifelong treatment and living alongside their cancer in an ongoing way.<sup>11</sup>

### Affective dimensions of precision survivorship: the dilemmas of hope

Hope is intrinsic to cancer care and survivorship for both patients and caregivers. As Corn *et al* note, hope induces ‘pathways and agency thinking’<sup>33</sup> towards a particular goal, bringing people together around shared objectives and playing a critical role at many points in the cancer journey.<sup>14 34 35</sup> More generally, hope is a crystallisation of the individual and collective desire to survive, to overcome and to prevail—desires that have powerful and complex effects in everyday clinical settings.<sup>36</sup> Hope can be harnessed and deployed in service of positive outcomes for patients with cancer and is important for caregivers’ health and well-being, which is strongly influenced by the patients’ level of hope—powerfully illustrating hope’s *relational* character.<sup>14 37</sup> Thinking about hope as relational means seeing hope not only as absent, present or otherwise quantifiable,<sup>38</sup> but rather as a complex *entanglement* of a wide range of social expectations (eg, hope for precision miracles, scientific breakthroughs, etc).<sup>39</sup> Discourses of hope are intrinsic to the clinical trials industry<sup>32</sup> where the relational *work* of generating hope keeps the ‘promissory bioeconomy’ of medical innovation moving forward.<sup>5</sup> In this way, hope can unify—binding people (patient, professional, carer, support network, researcher, regulator) together in pursuit of common purpose—but it can also become a source of disagreement, conflict and disorientation.<sup>40–42</sup> Hope’s perceived therapeutic value can place emotional demands on caregivers (and others), who must work to generate, maintain and protect hope as

a way of contributing to the patient's care and potential survival<sup>13 43 44</sup> as well as to the potential survival of future patients.<sup>12 32</sup>

Social science researchers such as Arlie Hochschild<sup>45</sup> have written about the *performative* dimensions of emotion management, where individuals invest considerable effort shaping their inner emotions—or, at least, moderating their public expression of these emotions—to meet the demands of their situation and the expectations of their family/community/society. In this sense, hoping is (hard) work that is often undertaken *collectively*, as different individuals—patients, carers, healthcare professionals and so on—encourage one another and co-create hope through implicit agreement.<sup>5 12 32</sup> Ambiguous prognoses, for example, where novel treatments are extending survival in the context of emerging evidence, thus increase the complexity of the emotion work performed by caregivers<sup>46</sup> as they co-construct hopeful 'future-time' with patients and professionals<sup>47</sup> and also work alongside patients to navigate the despair, alienation and anguish that cancer treatment (still) often entails.<sup>32</sup>

In this paper, we draw from our analysis of interviews with informal caregivers to untangle some of the dimensions of hope—as collectively produced through both clinical and emotional work—and to provide new insights into how the relationality of hope is being reconfigured through developments in precision oncology.

## METHODS

### Context

Taking an interpretive approach to research design, data collection and analysis, this article draws on data from in-depth, semi-structured interviews with 28 informal caregivers of people living with cancer and receiving targeted/immunotherapies. Interviews were conducted from May 2020 to August 2021 in Australia as part of a broader qualitative study focused on contemporary experiences of cancer care in the era of precision oncology.<sup>11</sup> The study involved a collaboration between health social scientists and clinician–researchers across three institutions and was aided and supported by five cancer-related consumer groups. Patients, caregivers and healthcare professionals were interviewed for the study. Following Pope *et al's* guidance for assessing the validity and relevance of qualitative research,<sup>48</sup> we provide below a clear exposition of data collection and analysis methods; each finding is supported by a range of data excerpts, including outliers or contradictory examples; and the research is placed in dialogue with an extensive literature drawn from both social science and clinical traditions (see Background – above).

### Patient and public involvement

Patients were not involved in the study design/conduct.

### Sampling and recruitment

This paper reports on the caregiver component of the study. Caregivers were recruited via convenience sampling through patients who were participating in the broader study. Using a purposive sampling method, potential patient participants who had sought out, tested for and/or experienced targeted and/or immunotherapies during their cancer care were approached by a clinician, researcher and/or consumer group organiser to explain the study. If they expressed interest in participating, participants were contacted via phone to initiate the informed written consent process and to schedule an interview via video or phone call. Patients were asked if they would like to nominate a partner, family member and/or friend who played a role in their care to be invited to participate in an interview. The researchers then contacted the nominated caregivers. Interested caregivers were provided with an information sheet outlining the aims of the study and were contacted to schedule an interview. To be included, carers had to have been nominated by a patient participant, be 18 years old or older and proficient in English. Participant recruitment continued until there was consensus among research team members that saturation had been reached.

### Data collection

Interviews were semi-structured and iteratively explored a range of issues around participants' lived experience of caring for someone with cancer in the context of targeted treatments and/or immunotherapies. Caregivers were asked about their experiences of their loved one's diagnosis, treatment and care, and their experiences of supporting them through these events. The caregiver interviews were conducted by AP, a sociologist with experience in in-depth qualitative interviewing in sensitive contexts. Interviews were conducted remotely, via video-call (due to COVID-19 public health measures), which facilitated geographical diversity across Australian states. Interviews lasted between 22 and 105 min (mean: 58 min), were audio-recorded and transcribed in full. Transcripts were deidentified, and each participant was assigned a code. Interviews did not focus specifically on hope, but this was a key issue raised by participants. The findings are derived inductively from analysis of participants' interviews.

### Analysis

A systematic thematic analysis—driven by the framework approach<sup>49 50</sup>—was conducted using NVivo V.11 software as a data management tool. The framework approach was initially developed in the context of conducting applied qualitative research.<sup>50</sup> It is a grounded, dynamic, systematic and comprehensive approach designed to facilitate retrieval of original data, comparisons between and within cases and a collaborative approach to data analysis.<sup>50</sup> Analysis involved the following steps: (1) Familiarisation: researchers (KK, LWV and AB) reviewed all caregiver transcripts, observing patterns and contrasts.



(2) Identification of thematic framework: From this initial coding, a thematic framework was developed (KK, LWV and AB), shaped by the research aims, emergent issues raised by participants and analytical themes arising from patterns in the data. (3) Application of themes to text: transcripts were recoded by applying the thematic framework. (4) Charting: Using the codes, key excerpts of data were brought together to facilitate refinement of themes and identification of anomalies and contrasts across transcripts. (5) Mapping and interpretation: using these charts, associations were clarified, and explanations developed, moving towards an overall interpretation of the data (KK, LWV, AB and MP). A sociologist experienced in qualitative data analysis (LWV) led the initial coding and application of the thematic framework. Framework development and interpretation were collaborative stages involving a team of social scientists (KK, LWV, AB and MP) with experience in qualitative data analysis in the domain of health and illness. The analysis was shared and discussed with the wider research team, including clinician–researchers, to confirm consistency and credibility of the interpretation. Analytical rigour was enhanced by searching for negative, atypical and conflicting or contradictory items in coding and theme development.

## RESULTS

### Participant characteristics

Informed written consent was obtained from 28 caregivers (16 men and 12 women, aged between 18 and 80) who then participated in one-on-one, semi-structured interviews. As part of the study design, participants were offered a follow-up interview approximately 6 months after their initial interview, with the aim of eliciting longitudinal insights, including reflections on changing prognoses and experiences of treatment. Nine caregivers participated in a follow-up interview. The sample included people caring for those living with neuroendocrine (12), lung (11), breast (2), rare (2) and brain (1) tumours. Most of the nominating patients had commenced (and in some cases ceased) precision cancer treatment in the 2 years prior to their first interview, although a few had longer precision journeys (in one case over 10 years). Caregivers included spouses (15), adult children (6), friends (3), parents (2), other relative (1) and support worker (1). Three patients (with rare, neuroendocrine and lung cancers) nominated two caregivers who were both interviewed, and one patient (neuroendocrine cancer) nominated three caregivers, all of whom were interviewed. Most caregivers—and the patients who nominated them—were Australian citizens with Anglo/European heritage. One caregiver and three nominating patients were Australians with South-East Asian heritage, and one nominating patient had Aboriginal and Anglo-Australian heritage. Most caregivers and their nominating patients were employed in (or had retired from) professional or managerial roles (eg, teachers, nurses, engineers) although the sample also included transport

**Table 1** Participant characteristics

| Participant characteristic  | n=28 (%) |
|---|----------|
| Caregiver sex   |          |
| Male  | 16 (57)  |
| Female  | 12 (43)  |
| Caregiver relationship to patient   |          |
| Spouse  | 15 (54)  |
| Adult child   | 6 (21)   |
| Parent  | 2 (7)    |
| Sibling   | 1 (4)    |
| Friend  | 3 (11)   |
| Support worker  | 1 (4)    |
| Patient cancer type*  |          |
| Neuroendocrine  | 12 (43)  |
| Lung  | 11 (39)  |
| Breast  | 2 (7)    |
| Rare  | 2 (7)    |
| Brain   | 1 (4)    |
| Caregiver location  |          |
| New South Wales   | 9 (32)   |
| Queensland  | 8 (29)   |
| Victoria  | 5 (18)   |
| Western Australia   | 4 (14)   |
| South Australia   | 1 (4)    |
| Australian Capital Territory  | 1 (4)    |
| Caregiver age   |          |
| 30 and under  | 4 (14)   |
| 31–50   | 6 (21)   |
| 51–70   | 12 (43)  |
| Over 70   | 6 (21)   |
| *Some patients nominated more than one caregiver. Numbers in this table reflect the number of caregivers caring for patients with a particular cancer type. |          |

workers, cleaners, farmers and retail workers. [Table 1](#) provides further details about caregivers' characteristics, including age and geographical diversity.

### Precision-induced hope

The sense of hope induced by targeted/immunotherapies was powerfully evident across many of the caregiver interviews. Caregivers routinely described themselves and their loved ones as 'privileged', 'thankful' and 'lucky' to have access to these new therapeutic pathways, often noting how recently precision treatments for the particular tumour in question had been discovered, approved and/or funded. As the quotes in [table 2](#) illustrate, many of the interviewees saw the rise and availability of precision therapies in oncology as a *hopeful development*. The ability to access these therapies was often articulated in contrast to others who did not have this access, for

**Table 2** Indicative quotes: precision-induced hope

| Participant*                                | Indicative quote  |
|---|---|
| Spouse, M, 70+, neuroendocrine cancer       | Oh, I think we're very, very privileged. We are. We're very grateful that it is there for us to use, yes. Yeah, so we are. We're very, very grateful and we just pray and hope that it's going to have some positive effect on the tumours.   |
| Daughter, F, 51–70, lung cancer             | We were very positive yesterday. I couldn't wait to talk to my brother. Yeah, we're feeling really good, and blessed too. Obviously blessed and thankful. I think we're all hoping for the magic bullet for cancer, but this immunotherapy, it's been fantastic. And I hope a lot of families benefit from it. It's great. [later] It was like winning a prize, I recall. It was like, "Oh, we won. Your cancer is eligible for this new immunotherapy thing."  |
| Daughter, F, <30, lung cancer               | I'm just really happy that we're in this day and age and not even 10, 20 years ago when this [drug] potentially wasn't around.  |
| Spouse, M, 51–70, neuroendocrine cancer (a) | Yeah, well I was just elated. I just thought like, "Here we go. Something's happening. We can do something. We can have a fight." [later] It's just exciting to see that all these people are actually putting all this effort into [neuroendocrine cancer] all of a sudden and they're coming up with all these strange ideas.   |
| Spouse, M, 51–70, lung cancer               | When we first got the alectinib, the price was on the box. For a month, it was AUD \$6000.(...)The month that she was diagnosed with cancer, alectinib went on the PBS [Pharmaceutical Benefits Scheme] that month. So we were getting the alectinib for AUD\$6.50, as opposed to the actual price on the box. (...) We thought, "Wow, we timed that well." (...) If we had to pay the full price, we probably could have done it, but it'd be a huge strain on our finances. But yeah, so we're lucky. Got lucky that we're in Australia. If she was in the [country of birth], she wouldn't be alive today, probably. |
| Sister, F, 51–70, brain cancer              | Well, I think it was amazing that he had access to it. Extremely, extremely, extremely lucky, like a fluke really. He's the only one in Australia that I know of that is having this, unless there are trials now. I'm not sure if there's trials in Australia. So he's extremely lucky, and I think everyone should have access to it.   |
| Spouse, M, 51–70, breast cancer             | [I knew] nothing. When I heard that, "Okay, this is this type of cancer and we've got this drug here which is perfect to target you. You're one of the lucky ones." I remember them saying that, that, "You're the lucky ones because this is made for the type of cancer you've got.   |
| Spouse, M, 51–70, neuroendocrine cancer (b) | I wasn't aware that there was any targeted therapy before, for any sort of cancer. So, it was completely new to me and it was terrific. You couldn't ask for anything more. The cancers were all, most of them were still there, but they'd reduced in size. Some had gone, but a lot of them had stayed. But I'd never heard of that sort of treatment being as effective before.  |
| Spouse, M, 51–70, neuroendocrine cancer (b) | If you start doing chemo, well that's the beginning of the end from my perspective. Not that I ever said that to [patient], but that's how I felt. But then, after the oncologist explained everything properly and we understood that it was an injection once a month and this could go on forever, well, you felt much more comfortable about things.  |
| Son, M, <30, lung cancer                    | I know that we may have to go through chemo down the line, because, from what I've been told, it's all a bit hazy, but I think the targeted therapy will reach a point where it won't have the effects, it won't have the success that it does and then she'll have to resort to chemo. But yeah, it really has just allowed us to have valuable time as a family.  |

\*Participants are identified in data tables by their relationship to the patient, sex (M/F), age range and patient cancer type. Participants with same information are distinguished by the addition of, for example, (a).

example, people with different cancer types or living in places/times without these options. 'Precision' care was thus seen to open a new door to hope,<sup>3</sup> a door held open by the Australian healthcare system's investment in and subsidising of 'cutting-edge' treatments. In Australia, cancer care is financed through a complex mix of Federal and State funding, private health insurance and out-of-pocket funds, and delivered by both the public and private hospital systems. Caregivers emphasised their gratitude for the Pharmaceutical Benefits Scheme, through which the government subsidises (some) precision treatments, and without which most said they would have struggled to pay for such therapies.

Until their loved one's cancer diagnosis, many caregivers professed to having had no prior knowledge of precision therapies, how they worked or acted in/on the body and what that might mean for their and their loved one's shared present and/or future. Reflecting on their responses to learning of the existence and potential of precision therapies, caregivers' accounts were strongly underpinned by the fear of—and relief at

avoiding—chemotherapy and radiation. Often they associated chemotherapy, to some extent, with hopelessness and debilitating side effects, and thus perceived precision therapies as offering greater hope in terms of *both* life extension and quality of life. However, as carers, patients and clinicians navigated the uncertain waters of precision treatment, the hope and gratitude invested in medical innovation was moderated by everyday experiences of scans, side effects, results, costs and ongoing logistical struggles. In the follow-up interviews, several caregivers expressed gratitude for the time (together) that the precision treatments had already provided, irrespective of how long this could continue. This pointed to the importance of considering hope as relational, which we focus on below.

### Hope as relational: from hope as 'work' to obligation

As illustrated by caregivers' perspectives presented in [table 2](#) and in the interviewees' accounts more broadly, precision therapeutics initially offered caregivers relief and comfort through the knowledge that the 'science' of cancer

**Table 3** Indicative quotes: hope as relational: from hope as ‘work’ to obligation

| Participant*                          | Indicative quote   |
|---------------------------------------|--|
| Sister, F, 51–70, brain cancer        | You just have to be hopeful that he'll have this treatment again and he'll deal with it quick, if that's what it was. So yeah, hopeful. Otherwise it's shit. So you've got to be hopeful.  |
| Spouse, M, 51–70, lung cancer (a)     | (W)hen your friends and acquaintances hear you've got cancer, they all tend to say, "Oh look, she's a strong girl. You'll get through this. She's strong. We're praying for you. You'll get through this." And a few people said that, and I didn't say anything, but I found it really irritating. That really bugged me because what I thought was, "No, we're not walking off into the sunset hand in hand to fight the good fight. This is a bloody ugly street fight." There's nothing nice about it. There's nothing noble about it. It's not Joan of Arc on a horse with a shield and a sword and, "We're going to slay this cancer dragon." It's nothing like that. It is totally devastating. |
| Daughter, F, 51–70, lung cancer       | It was the unknown. We hadn't been down this path before. We hadn't experienced this. So, she wasn't frightened, but she was concerned, and I guess her concern was loss of independence and becoming reliant on ongoing medical care for the rest of her life. So we talked about it and, I said, "Give it a go. Just give it a crack and just see." And I'm glad we did, because she tolerated it really well and hasn't had any problems.   |
| Spouse, M, 51–70, lung cancer (a)     | The last meeting she was a bit disappointed with because there was no reduction. So she was a little bit down about that. But as I said to her, "It's better than spreading."  |
| Spouse, M, 51–70, breast cancer       | You have to be realistic about it, but you can't let what might happen overwhelm what is happening. So, projecting to the future and saying, "Well, what if they find more?" Yet again, it's those techniques of being positive, keeping things normal, not changing routine. Changing as little as possible, because you've got to establish family routine. (...) I can't see the value in being negative or dwelling on a negative outcome. It will take you back into that depressive state. You become a burden, for want of a better word. And you don't need that when your partner's battling such a serious illness, you don't want to be a burden there.                                     |
| Spouse, M, 51–70, lung cancer (a)     | And this one doctor confused a question and she mentioned something about the side-effects and the medication and the doctor just blurted out in front of everybody, the whole family, "Oh no, there's no [remission]. You will be on medication for the rest of your life." (...) Now, that was not what she needed to hear (...). And it was just blurted out so matter of factly by a doctor.   |
| Spouse, M, 51–70, lung cancer (b)     | He [oncologist] probably rubbed [her] up the wrong way immediately because he presented a very negative outcome immediately(...). Reading the notes at the time, they obviously hadn't been pre-prepared and it caught him by surprise. And because it caught him by surprise, he probably spoke in a way that he probably wouldn't have otherwise done, but that's where he killed a lot of hope in [her] because that's when he said, "You have stage four and there's no such thing as remission."(...) It really took a lot of positivity out of her response to the disease initially. So, yeah, it was quite devastating for us both.  |
| Spouse, M, 51–70, lung cancer (b)     | They don't understand how hurtful some of the stuff they can say is, and the effects it has on their patients. Almost like it's unconscious, I suppose. But anyway, as I said, in a social context he'd be probably very personable, people would like him. But as far as [she] was concerned, she would prefer someone to be a little bit more positive.  |
| Mother, F, 70+, neuroendocrine cancer | Give them the facts, sure. But in a way that it's not just all death and destruction. That there is maybe some light at the end of the tunnel with some research or something that's going to go on. "We're progressing all the time," and talk like that, I think. It's a better way of talking.  |

\*Participants are identified in data tables by their relationship to the patient, sex (M/F), age range and patient cancer type. Participants with same information are distinguished by the addition of, for example, (a).

treatment—including treatment options for their loved one's cancer type—was advancing. This provided a sense that new personalised options were emerging that would have seemed unlikely or impossible even a few years earlier. However, caregivers' stories of hope-in-precision also involved new relational complexities, and perceptions of precision often changed over time, as the follow-up interviews showed. One example of this complexity was a dialectical tension between hope and obligation.<sup>51</sup> Specifically, and as illustrated in table 3, caregivers frequently reflected that hope was *required* for treatment to be successful, and that it needed to be found or even manufactured. The *work* of generating or projecting hope<sup>51 32 45 52</sup> was consistently discussed within the caregiver interviews. In caregiver accounts, this work was positioned as pivotal to the precision journey: when patients professed concerns or disappointment, caregivers sought to engender in the patient the hope necessary for them to start or continue with precision treatment. At the same time, they

had to work hard to maintain their own hopefulness in order to avoid becoming a 'burden' to the patient.

Some caregivers observed that the social expectation to profess hope induced a sense of alienation, particularly in relation to people not involved in the everyday reality of cancer. The hopes of others, imposed on caregivers via hopeful talk or encouragement to be positive, was described, for example, as deeply 'irritating', signifying, for our participants, a fundamental misrecognition of the challenges of living with, and caring within, the precision-cancer milieu (ie, not as 'easy' or 'liberating' as one might imagine). Perhaps enhanced by the lack of traditional signifiers of cancer (eg, hair loss/nausea), experiencing precision therapy was seen as exacerbating the disorientations between recognition of suffering and performativity of hope, perseverance and determination, as the quotes in table 3 indicate.

Hope was also a prominent feature of therapeutic encounters. Just as caregivers felt an obligation to enact

hope relationally—to express and practice hope—so too did they see it as an obligation of clinicians to cultivate hope in clinical encounters. Several caregivers expressed a belief that maintaining hope should be a higher order priority for clinicians than managing expectation, which has often been a focus of discussion in and around effective clinical communication.<sup>53 54</sup> In several cases, caregivers discussed supporting the patient to find a new healthcare professional in response to ‘hurtful’ statements of hopelessness, illustrating the tightrope clinicians walk in navigating, negotiating and co-constructing hope with patients and caregivers.

As the indicative quotes in [table 3](#) illustrate, patients, caregivers and clinicians work (and sometimes struggle) to reframe hope in the precision-oncological context. For example, while clinicians may not use terms like ‘remission’ in this context, for patients and caregivers the absence or refusal of this term may be understood as ‘killing hope’. Evolving and unsettled evidence, and gaps in lay understandings of treatments and potential outcomes, may mean that patients, caregivers, clinicians and other social actors lack the necessary shared language or knowledge to successfully navigate the complexities of hope in the swiftly evolving landscape of precision therapeutics.

### Speculative hope and hope for the common good

From the caregivers’ perspective, hope spanned the individual and collective, the present and future, obligation and aspiration. The very concept of hope implies a goal or object—something that is hoped *for*. In the precision context, this was often oriented towards the prospect of medical innovation. In this dual focus on presently unfolding progress and as-yet-unknown future advances, caregivers articulated a sense of being part of a wider social phenomenon as well as being embedded in a deeply personal experience. Thus, individualised hopes—for survival, for the future life experiences that survival might bring, for minimal symptoms or side effects—were also considered in relation to the common good or benefit for future patients, caregivers and families.

Deliberation over benefit was far from stable and a source of ongoing renegotiation within families. For instance, some caregivers expressed frustration or fear that progress would not happen fast enough to benefit their relative/friend, but others were more sanguine, accepting that being at the cutting edge of innovation entailed being a ‘guinea pig’ (see [table 4](#)), in part to benefit others in the future. While the idea of lifelong treatment implied a lack of hope for some caregivers (for a return to normal life post cancer—see [table 3](#)), it opened up a hopeful vista of continuation for others (see [table 4](#)). For still others, especially older patients and caregivers, quality of life was more important than life-extending scientific breakthrough as they felt they had lived (a good) enough life.

The hope invested in the notion of ongoing scientific progress was often grounded in the fear that even successful treatments would likely stop working in the

future. This shadow of fear drove some caregivers to engage in the ‘hopeful work’ of advocacy, seeking out trials and treatments and/or lobbying for access and funding.<sup>12</sup> When precision treatments failed or side effects proved intolerable, caregivers and families were often forced to re-evaluate their early hopes for continuation of life, asking painful questions about if and where hope might now be found. Initial responses of relief and gratitude (see [table 2](#)) evolved into complex and fluctuating emotions, characterised by the need to provide consistent support in the face of uncertainty, hope and disappointment, compounded by fluctuating side effects and the fatigue of long-term life on treatment.

Hope, in this precision oncology context, spread across bodies, families, experts and fields of science, holding on to both the potential for an individual disease outcome and the altruism of the common good from participation in science and innovation. Hope, in this sense, was speculative both in terms of the outcomes for those they cared for, and the future possibilities that biomedical innovation may offer. This reflects the ethics of hope as about solidarity as well as about the individual prevailing, and in turn, how uncertainty binds to hope. That is, *being on the precipice*—of breakthrough or death—is a key affective relation permeating hope within the precision environment.

### DISCUSSION

The last decade or so has been transformative for practice and outcomes in oncology. The precision turn, variable as it is across cancer types, has radically reconfigured expectations around the outcomes of malignancy and introduced new vistas of hope and possibility for many (though not all).<sup>7–11</sup> What had not, until now, been adequately explored are laypersons’ perspectives on the precision turn in oncology and in particular, accounts of patients and caregivers. Here we have focused on caregiver perspectives, with a particular interest in their experiences of hope in and around precision, and its complexities in this swiftly evolving scene.

Interviews with these caregivers provide important insight into the emerging and evolving social world of precision oncology, and how those in supportive roles view and make sense of care and survivorship in this context. Hope, as it emerged, was a binding narrative within the interviews, but in complex and unexpected ways. Moving beyond simple binaries such as optimism/pessimism, realistic/unrealistic, ignorance/understanding, analysis of the caregivers’ interviews revealed the importance of relationships, values and commitment to (or faith in) science/innovation in mediating caregivers’ experiences of precision oncology and their orientation around hope, therein. What emerged was a picture of the relational nature of (precision-induced) hope and gratitude, the relational ‘work’ of upholding hope,<sup>5 45 52</sup> associated forms of obligation<sup>49</sup> and also the possibility of solidarity with future beneficiaries of experimental therapies.<sup>12 55</sup>

**Table 4** Indicative quotes: speculative hope and the common good

| Participant*                          | Indicative quote   |
|---------------------------------------|--|
| Spouse, M, 51–70, lung cancer (c)     | Well, I'm a supreme optimist. I think that they'll come up with a cure, so I'm not too worried. I think that she'll just keep going, and we'll keep doing the same thing. I think [oncologist] was actually talking about it, the next type of [targeted therapy] would be on the horizon soon. So if these two don't work, then there'll be probably something else or another trial or something, and this'll go on for a few more years, and then eventually they'll have a cure and everything will be back to normal.   |
| Spouse, M, 31–50, rare cancer         | Oh, it [possibility of entering a trial] was pretty exciting actually. I thought, "Okay, great. Maybe there's this magic pill out there." Then [she] was sort of excited and I was – I'm a little bit more reserved and go "Okay, I'll wait and see until it happens."   |
| Spouse, M, 70+, neuroendocrine cancer | I mean, if, in the end, it helps somebody. I mean, the only way we can help other people and develop things is to – somebody's got to be the guinea pig in the end.  |
| Spouse, M, 51–70, lung cancer (a)     | My biggest fear is if the targeted therapy that she's currently on doesn't keep working, then we're in trouble. But, as they say, they are developing all the time.(...) If that stops working, we have to hope the next one comes along, or we have to hope we can get involved with trials. But that's probably my biggest fear that got me to understand a bit more about the targeted therapy. And also, just as they keep saying, the research keeps advancing, so there is always hope that they are constantly advancing and (...) down the track there will be the next generation of drugs that will be a back stop if she feels, or they feel, the doctors feel, "Well, let's move onto the next one to keep this in check."   |
| Spouse, M, 70+, neuroendocrine cancer | They did mention [a trial], but it would mean that [she] would have to go into hospital, I think it was once a week for 8 hours, for this clinical trial(...) I mean, we are sort of getting older and(...) I think [she] is still looking at this thing about the quality of life, and not the quantity. (...) So we're thinking, "Well..." And at our age, quite frankly, we've sort of had a good life. We're just sort of saying, "Look, we've had a good life. If this is the end of the story, well, that's fine. We've done quite well. We've done very well."  |
| Mother, F, 70+, neuroendocrine cancer | I read everything in the newspapers about trials, but they're all in 5 years' time, 10 years' time, and all this. What's the use of that for Christ's sake? They're dying now.   |
| Spouse, F, 51–70, lung cancer         | [We thought] you have your chemo treatment and all that and then this would be the icing on the cake. (...) Once you've had the immunotherapy, this is going to be the be all and end all of getting rid of the cancer. And once you've had that year, then that's it. That's how it felt. But then when it didn't work, it was like, "Oh shit, we've only had four treatments. Does that mean the end of it?"   |
| Spouse, M, 70+, lung cancer           | Well, I didn't know much about it. I mean, I just checked, showed on the internet, and it seems to work with her because initially the cancer shrank. It was 22 millimetres and then it shrank. After 3 months, it shrank to 18 and so we were in good hope that the medication is effective. But then, with the time, the virus itself changed or mutated the virus cells and the first medicine didn't have any effect anymore. (...) And so, yeah, I was in shock again somehow. Because this was a treatment the doctor said was 95% it's working and it is a good alternative and all this, and then just like somebody takes the ground off your feet. And so then we were, of course, talking about alternatives, but obviously they don't have much alternatives except chemotherapy, and that's what they put her on. |

\*Participants are identified in data tables by their relationship to the patient, sex (M/F), age range and patient cancer type. Participants with same information are distinguished by the addition of, for example, (a).

That is, caregivers' experiences of precision treatments contained a mix of the *enabling* features in terms of patient benefits, increased survival and so on, but also *normative* expectation including the ways in which new treatment trajectories introduce new sets of requirements and expectations across patients, carers and clinicians in everyday life.

The results also introduce some important concepts as to how we think about care in the context of precision oncology, and indeed, resonate with much of the broader literature on both hope and caring relations.<sup>13–23</sup> First, hope is less a property of the individual (patient or caregiver) and more a collective accomplishment, negotiated across complex social relations and expectations, and underpinned (or undermined) by the political economy of healthcare and innovation. Second, hope is a form of *work*—it needs to be generated and projected—with caregivers deeply involved in this practice of hope. This work is not straightforward, often involves considerable suffering, and, as one participant articulated, can be 'a bloody ugly street fight' despite the optics of optimism.

Finally, these caregivers' perspectives accentuate the power of *hope in scientific progress*—in this case genomic—as mobilising, animating and directing the scene of oncological survivorship. Although experiences of cancer have long been tied to notions of scientific progress, treatment breakthroughs and therapeutic innovation,<sup>56</sup> hope in the context of precision therapeutics has been positioned as particularly precarious.<sup>5</sup> This can be seen in biomedical research papers and broader commentary alike, with frequent use of phrases such as 'hope or hype' or 'hope or reality'.<sup>57–59</sup> Time-to-market, and therapeutic pipelines more broadly, take years and sometimes decades to come to fruition—if, indeed, they bear fruit at all.<sup>60</sup> Yet experimental precision oncology trials involving human participants who must be matched, clinically and genetically, to the requirements of the trial<sup>3</sup> offer a sense that medical innovation is happening in real time. In the caregivers' accounts, biographical time competes with clinical time,<sup>61</sup> the pace of innovation set against the progression of disease and (almost) inevitable failure of currently available treatments.<sup>12</sup> Sustaining hope *with and*



for the patient is grounded in the hope that innovation will arrive in time to give them more (life-)time together. This precarious hopefulness suggests that precision therapeutics, as they stand, have mixed effects, the subtleties of which, including factors beyond disease impacts, deserve significant exploration. In this context, hope is not only emotional but also *moral labour*,<sup>62</sup> which operates in a dialectic tension between how *I* may benefit now and how the future *we* may benefit, later. For caregivers, the moral labour of mobilising and maintaining another person's hope involves an additional relational dimension, layered on top of the normative (moral) imperative to be a 'good' carer by working to achieve hope in another. This relational, emotional and moral labour underpins the potentiality of cancer innovation.<sup>12 32</sup> The hope-precision nexus is thus an evolving *ethical system*, whereby participation in trials, acceptance of novel drugs with uncertain outcomes, advocacy for access to (subsidised) therapeutics and so on involves a mix of concern for the self and concern for the other (present or future).

By revealing these more nuanced dimensions of hope—as precarious, as relational, as work—our findings make explicit not only the positivity of hope but also its painful potential. Offering hope is not always a kindness and might even become toxic in some circumstances.<sup>63</sup> Certainly, hope can be difficult to manage in terms of expectations versus realities and might even be harmful when inaccurately deployed or internalised (ie, when the hopeful future does not arrive). In essence, hope is not universally or unquestionably positive, it can also be difficult and, unfortunately, cannot inoculate against suffering.

This paper has focused on the perspectives of informal caregivers, using semi-structured in-depth interviews conducted with caregivers as the primary data source. In so doing, we have been able to highlight this previously neglected perspective, as well as the complex interplay between individual prognoses, interpersonal dynamics, institutional pressures, social expectations and the political and economic dimensions of therapeutic innovation. We acknowledge, however, that conducting a full dyadic analysis of the patient-participant and caregiver data sets together might yield further insights. The context in which the study was conducted (ie, the first years of the COVID-19 pandemic) was both a limiting and enabling factor. The pivot from in-person, hospital-based recruitment to online recruitment drawing on cancer support groups, potentially led to a less ethnically and socio-economically diverse sample but facilitated access to a much more diverse sample in terms of cancer type and geographical location. The experiences of people caring for patients with neuroendocrine cancer, for example, have rarely been included in studies of precision cancer care. As we have noted elsewhere, the COVID context had a deep impact on patients' and caregivers' experiences of cancer care<sup>64 65</sup> and may have affected participants' orientations towards the future. The study should, therefore, be viewed in the context of the place (Australia) and time

(2020–2021) in which it was conducted. Nevertheless, this study of caregivers' experiences provides new insights into the 'social life' of precision oncology. In particular, it underlines the ways that innovation and change in the precision era can rapidly reconfigure the parameters of hope (unclear therapeutic trajectories, uncertain survival chances), creating new and difficult relational moments and experiences in everyday life. How patients, caregivers and clinicians alike navigate between uncertain chances of success and hopeful possibility and potential will likely remain a challenge in years to come.

#### Author affiliations

<sup>1</sup>Sydney Centre for Healthy Societies; School of Social and Political Sciences, The University of Sydney, Sydney, New South Wales, Australia

<sup>2</sup>Department of Political Science, University of Vienna, Wien, Austria

<sup>3</sup>Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children's Hospital Randwick, Randwick, New South Wales, Australia

<sup>4</sup>School of Clinical Medicine, UNSW Medicine and Health, Randwick Clinical Campus, Discipline of Paediatrics, UNSW, Sydney, New South Wales, Australia

<sup>5</sup>Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia

<sup>6</sup>Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia

<sup>7</sup>Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

<sup>8</sup>Department of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

<sup>9</sup>Faculty of Medicine, The University of Queensland, Saint Lucia, Queensland, Australia

**Twitter** Katherine Kenny @kennykatherine, Leah Williams Veazey @leahmouse and Michelle Peterie @MichPeterie

**Contributors** The project was designed and developed by AB, KK, BP, CW, MI, MK and ZL. Data for this paper were collected by AP. Data analysis was led by KK, LW and AB, with input from MP, AP, BP, CW, MI, MK and ZL. All authors contributed to the drafting and revising of the manuscript and approved the final version of the manuscript. KK accepts responsibility for the article's overall content as guarantor.

**Funding** This work was supported by an Australian Research Council Discovery Projects grant (Project ID: DP190100745). Prof Claire Wakefield is supported by the National Health and Medical Research Council of Australia (APP2008300). Dr Katherine Kenny is supported by an Australian Research Council DECRA Award (DE22101498).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by Royal Brisbane & Women's Hospital Human Research Ethics Committee. Ref No. HREC/2019/QRBW/50345: Precision and the person: A sociological study of therapeutic innovation in cancer care. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. No additional unpublished data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Katherine Kenny <http://orcid.org/0000-0001-9088-5671>

Leah Williams Veazey <http://orcid.org/0000-0002-0173-3690>  
 Barbara Prainsack <http://orcid.org/0000-0002-6335-1532>

## REFERENCES

- DeVita VT, Chu E. A history of cancer chemotherapy. *Cancer Res* 2008;68:8643–53.
- Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. *Ann Transl Med* 2018;6:166.
- Dam MS, Green S, Bogicevic I, et al. Precision patients: selection practices and moral pathfinding in experimental oncology. *Social Health Illn* 2022;44:345–59.
- Kenny K, Broom A, Page A, et al. A sociology of precision-in-practice: the affective and temporal complexities of everyday clinical care. *Social Health Illn* 2021;43:2178–95.
- Kerr A, Chekar CK, Ross E, et al. *Personalised cancer medicine: future crafting in the genomic era*. Manchester: Manchester University Press, 2021.
- Tutton R. *Genomics and the reimagining of personalized medicine*. London: Routledge, 2016.
- Tsimberidou AM, Fountzilias E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. *Cancer Treat Rev* 2020;86:102019.
- Chow EJ, Antal Z, Constine LS, et al. New agents, emerging late effects, and the development of precision survivorship. *JCO* 2018;36:2231–40.
- Koczwara B, Thornton-Benko E, Cohn RJ, et al. Personalised cancer care in the era of precision medicine. *Aust J Gen Pract* 2021;50:533–7.
- Lassen UN, Makaroff LE, Stenzinger A, et al. Precision oncology: a clinical and patient perspective. *Future Oncol* 2021;17:3995–4009.
- Broom A, Kenny K, Williams Veazey L, et al. Living (well) with cancer in the precision era. *SSM - Qualitative Research in Health* 2022;2:100096.
- Ackerman SL. Promising precision medicine: how patients, clinicians and caregivers work to realize the potential of genomics-informed cancer care. *New Genetics and Society* 2022;41:196–215.
- Thomas C, Morris SM. Informal carers in cancer contexts. *Eur J Cancer Care (Engl)* 2002;11:178–82.
- Thomas C, Morris SM, Harman JC. Companions through cancer: the care given by informal carers in cancer contexts. *Soc Sci Med* 2002;54:529–44.
- Olson RE. *Towards a sociology of cancer caregiving: Time to feel*. London: Routledge, 2016.
- Olson RE. Managing hope, denial or temporal anomie? Informal cancer carers' accounts of spouses' cancer diagnoses. *Soc Sci Med* 2011;73:904–11.
- Ussher JM, Tim Wong WK, Perz J. A qualitative analysis of changes in relationship dynamics and roles between people with cancer and their primary informal carer. *Health (London)* 2011;15:650–67.
- Kayser K, Watson LE, Andrade JT. Cancer as a "we-disease": examining the process of coping from a relational perspective. *Families, Systems, & Health* 2007;25:404–18.
- Hodges LJ, Humphris GM, Macfarlane G. A meta-analytic investigation of the relationship between the psychological distress of cancer patients and their carers. *Soc Sci Med* 2005;60:1–12.
- White N, Newman E. Shared recovery: couples' experiences after treatment for colorectal cancer. *Eur J Oncol Nurs* 2016;21:223–31.
- Broom A, Kenny K, Kirby E. Entangled and estranged: living and dying in relation (to cancer). *Sociology* 2020;54:1004–21.
- Marzano M. Lies and pain: patients and caregivers in the "conspiracy of silence." *Journal of Loss and Trauma* 2009;14:57–81.
- Lawton J. *The dying process: patients' experiences of palliative care*. London: Routledge, 2000.
- Kenny K, Broom A, Kirby E, et al. Terminal anticipation: entanglements of affect and temporality in living with advanced cancer. *Subjectivity* 2017;10:374–92.
- Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. *J Hematol Oncol* 2020;13:58:58..
- Duruisseaux M, Besse B, Cadranell J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. *Oncotarget* 2017;8:21903–17.
- Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. *Annals of Oncology* 2020;31:1056–64.
- Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985–2016. *Breast* 2017;31:46–50.
- Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med* 2022;386:1143–54.
- Yeo B, Kotsori K, Mohammed K, et al. Long-Term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. *Breast* 2015;24:751–7.
- Rubin MA. Health: make precision medicine work for cancer care. *Nature* 2015;520:290–1.
- Kerr A, Cunningham-Burley S. Embodied innovation and regulation of medical technoscience: transformations in cancer patienthood. *Law Innov Technol* 2015;7:187–205.
- Corn BW, Feldman DB, Wexler I. The science of hope. *Lancet Oncol* 2020;21:e452–9.
- Conway MF, Pantaleao A, Popp JM. Parents' experience of hope when their child has cancer: perceived meaning and the influence of health care professionals. *J Pediatr Oncol Nurs* 2017;34:427–34.
- Olsman E, Leget C, Onwuteaka-Philipsen B, et al. Should palliative care patients' hope be truthful, helpful or valuable? an interpretative synthesis of literature describing healthcare professionals' perspectives on hope of palliative care patients. *Palliat Med* 2014;28:59–70.
- Steinberg DL. The bad patient. *Body & Society* 2015;21:115–43.
- Duggleby W, Lee H, Nekolaichuk C, et al. Systematic review of factors associated with hope in family carers of persons living with chronic illness. *J Adv Nurs* 2021;77:3343–60.
- Brown N. Metrics of hope: disciplining affect in oncology. *Health (London)* 2015;19:119–36.
- Fitzgerald D, Callard F. Social science and neuroscience beyond interdisciplinarity: experimental entanglements. *Theory, Culture & Society* 2015;32:3–32.
- Olver IN. Evolving definitions of hope in oncology. *Curr Opin Support Palliat Care* 2012;6:236–41.
- Daneault S, Dion D, Sicotte C, et al. Hope and noncurative chemotherapies: which affects the other? *J Clin Oncol* 2010;28:2310–3.
- Saltz LB. Precision oncology giveth and precision oncology taketh away. *Lancet Oncol* 2019;20:464–6.
- Lewis S, Broom A, Kenny K, et al. Cancer caregivers' experiences of prognosis in Australia: a qualitative interview study. *BMJ Open* 2020;10:e032361.
- Perakyla A. Hope work in the care of seriously ill patients. *Qual Health Res* 1991;1:407–33.
- Hochschild AR. *The managed heart commercialization of human feeling (updated, with a new preface)*. Berkeley: University of California Press, 2012.
- Olson RE, Connor J. When they don't die: prognosis ambiguity, role conflict and emotion work in cancer caregiving. *Journal of Sociology* 2015;51:857–71.
- Brown P, de Graaf S. Considering a future which may not exist: the construction of time and expectations amidst advanced-stage cancer. *Health, Risk & Society* 2013;15:543–60.
- Pope C, Ziebland S, Mays N. Qualitative research in health care. analysing qualitative data. *BMJ* 2000;320:114–6.
- Pope C, Ziebland S, Mays N. Analysing qualitative data. In: Pope C, Mays N, eds. *Qualitative research in health care*. 3rd ed. Oxford: Blackwell Publishing, 2006: 63–81.
- Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess B, eds. *Analyzing qualitative data*. Routledge, 2001: 187–208.
- Petersen A. *Hope in health: The socio-politics of optimism*. London: Springer, 2015.
- Hochschild AR. Emotion work, feeling rules, and social structure. *American Journal of Sociology* 1979;85:551–75.
- Marchiano EJ, Birkeland AC, Swiecicki PL, et al. Revisiting expectations in an era of precision oncology. *Oncologist* 2018;23:386–8.
- Ziegelstein RC. Perspectives in primary care: knowing the patient as a person in the precision medicine era. *Ann Fam Med* 2018;16:4–5.
- Prainsack B. The "we" in the "me" *Science, Technology, & Human Values* 2018;43:21–44.
- del Vecchio Good M-J, Good BJ, Schaffer C, et al. American oncology and the discourse on hope. *Cult Med Psych* 1990;14:59–79.
- Muller C, Yurgelun M, Kupfer SS. Precision treatment and prevention of colorectal cancer—hope or hype? *Gastroenterology* 2020;158:441–6.
- Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: hope, hype or both? *Leuk Res* 2016;48:73–7.

- 59 Sajjadi E, Venetis K, Scatena C, *et al*. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? *Ecancermedicalscience* 2020;14:1150.
- 60 Madhavan S, Beckman RA, McCoy MD, *et al*. Envisioning the future of precision oncology trials. *Nat Cancer* 2021;2:9–11.
- 61 Rhodes T, Bernays S, Terzić KJ. Medical promise and the recalibration of expectation: hope and HIV treatment engagement in a transitional setting. *Soc Sci Med* 2009;68:1050–9.
- 62 Dragojlovic A, Broom A. *Bodies and Suffering: Emotions and Relations of Care*. New York: Routledge,
- 63 Ehrenreich B. *Smile or die: how positive thinking fooled America and the world*. London: Granta, 2010.
- 64 Page A, Broom A, Kenny K, *et al*. Experiencing the SARS-cov-2 pandemic whilst living with cancer. *Qual Health Res* 2022;32:426–39.
- 65 Broom A, Williams Veazey L, Kenny K, *et al*. The enduring effects of covid for cancer care: learning from real-life clinical practice. *Clin Cancer Res* 2023:F1–8.